High levels of pipeline activity are being observed in Peripheral Vascular Disease (PVD) treatment during 2019. Clinical development activities are being undertaken by more than 35 companies including 480 Biomedical Inc, Alucent Medical Inc, Anaeropharma Science Inc, AnGes MG Inc, AngioSoma Inc and others.
A Significant contribution to the Peripheral Vascular Disease (PVD) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Peripheral Vascular Disease (PVD) pipeline included 35 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Peripheral Vascular Disease (PVD) condition and increased access to investments is encouraging growth of Peripheral Vascular Disease (PVD) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Peripheral Vascular Disease (PVD) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Peripheral Vascular Disease (PVD) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Peripheral Vascular Disease (PVD) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Peripheral Vascular Disease (PVD). Further, orphan drug status, fast track designation, grants awarded and other special status for Peripheral Vascular Disease (PVD) pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Peripheral Vascular Disease (PVD) pipeline and formulate effective research and development strategies.
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Peripheral Vascular Disease (PVD) Pipeline candidates- - Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Peripheral Vascular Disease (PVD) drugs
- Late phase: Phase 3 and in-approval Peripheral Vascular Disease (PVD) drugs
Companies involved in the Pipeline- - Company overview
- Peripheral Vascular Disease (PVD) therapeutic treatment activities
Details for each Peripheral Vascular Disease (PVD) drug candidate- - Snapshot
- Drug Name
- Alternative Names
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
Other details - Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
Recent Peripheral Vascular Disease (PVD) therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news
Our reports have been used by over 10K customers, including:
Omega 3 Supplements Market Size, Share & Trends Analysis Report By Source (Fish Oil, Krill Oil), By Form (Soft Gels, Capsules), By Functionality, By End-user, By Distribution Channel, By Region, And Segment Forecasts, 2020 - 2027
Omega 3 Supplements Market Growth & Trends
The global omega...
KEY FINDINGS The global anticoagulants market is estimated to project a CAGR of 8.42% during the forecast period of 2021 to 2028. The key market growth drivers include, the surging approval of novel oral anticoagulants (NOAC), technical advancements, and the surging incidence of chronic diseases. MARKET INSIGHTS Anticoagulants...
The North America Wearable Patch Market would witness market growth of 10.41% CAGR during the forecast period (2020-2026). A wearable patch is alternately called electronic skin or smart patch. They are used to diagnosis, monitor diseases, and drug delivery. It is also helpful in maintaining the health of aging patients suffering from...
KEY FINDINGS The Asia Pacific cartilage repair market is estimated to project a CAGR of 16.84% during the forecast period, 2021-2028. The increasing need for sophisticated medical facilities, the growing prevalence of lifestyle diseases resulting in bone & joint ailments, and the rising R&D activities, are propelling the...
120 pages •
By Infiniti Research Limited
• Feb 2021
Global Hemodialysis Equipment Market 2021-2025 The analyst has been monitoring the hemodialysis equipment market and it is poised to grow by $ 3.57 bn during 2021-2025, progressing at a CAGR of 4% during the forecast period. Our report on hemodialysis equipment market provides a holistic analysis, market size and forecast,...
Summary SomaLogic Inc (SomaLogic) is a life science company that discovers, develops and commercializes life science research tools and clinical diagnostic products.The company’s products include SOMAscan assay and SOMAmer reagents. Its SOMAscan reagents is a proteomic platform that combines the properties of antibodies...
Global Glycobiology Market, By Product (Enzymes, Instruments, Reagents and Kits), By Application (Drug Discovery, Disease Diagnostics, Virology, Cell Biology, Oncology, Others), By End User (Research Institutes, Diagnostic Centers, Hospitals, Clinical Laboratories, Pharmaceutical & Biotechnology Companies, Others), By Region, Competition,...
KEY FINDINGS The Europe anticoagulants market is expected to record a CAGR of 8.48%, over the forecast period of 2021 to 2028. The region’s market growth is accredited to the rise in healthcare expenditure, the growing prevalence of venous thromboembolism (VTE) and atrial fibrillation, the increase in the geriatric and...
Transformational Health team provides critical insights into the Asian specialty generics market with this research service, highlighting growth opportunities, selected countries’ biopharmaceutical environment, and significant R&D, regulatory, and infrastructure reforms influencing its growth. The report examines similarities and contrasts...
The major factors attributing to the growth of the biosurgery market are increasing geriatric population, rising prevalence of chronic diseases and related surgeries, and a strong focus on R&D leading to the launch of new and advanced products. The global increase in the number of geriatrics population and obese people is likely to...
Surgical Procedures Performed
Chronic Disease Prevalence
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.